• Floriana Elvira Ionică
  • Simona Negreș
  • Oana Cristina Șeremet
  • Cornel Chiriță
Keywords: anti-obesity pharmacotherapy, diethylpropion, lorcaserin, orlistat, phentermine/topiramate


Background and Aims: In the last three decades, obesity and its related co morbidities has quickly increased. Sometime, obesity was viewed as a serious health issue in developed countries alone, but now is recognized as a worldwide epidemic, and its associated costs are enormous. Obesity is related with various diseases, like hypertension, type 2 diabetes mellitus (T2DM), dyslipidemia, chronic cardiovascular diseases, respiratory conditions, alongside chronic liver diseases, including non- alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). This review purpose is to provide data on the current anti-obesity drugs, also available and in the development. Material and Methods: We searched MEDLINE from 2006 to the present to collect information on the anti-obesity pharmacotherapy. Results and Conclusions: In the patients with obesity related comorbidities, there may be an adaptation of the anti-obesity pharmacotherapy to the patients’ needs, in respect to the improvements of the cardiometabolic parameters. Although their efficacy was proven, the anti-obesity pharmacotherapies have presented adverse events that require a careful monitoring during treatment. The main obstacle for approve new drugs seems to be the ratio between the risks and the benefits, because of a long-time background of perilous anti-obesity drugs.

How to Cite
Ionică, Floriana, Simona Negreș, Oana Șeremet, and Cornel Chiriță. 2016. “PHARMACOTHERAPY IN THE TREATMENT OF OBESITY”. Romanian Journal of Diabetes Nutrition and Metabolic Diseases 23 (4), 415-22.
Review Articles